Table 1 Clinical and demographic characteristics of all participants.
From: Profiling of lipid mediators and oxylipins in SARS-CoV-2 infection associated thrombosis
Characteristics | Healthy control subjects | SARS-COV-2-positive patients | ||
|---|---|---|---|---|
Category (N) | 300 | Mild (1255) | Severe (153) | Critical (323) |
Age, median (IQR), years | 69 (58–82) | 67 (55–77) | 73 (64–85) | 78 (70–87) |
Male, n (%) | 172 (57) | 726 (58) | 94 (61) | 225 (70) |
BMI, median (IQR), Kg/m2 | 22.8 (19.8–23.8) | 23.4 (21.1–26.1) | 23.5 (20.5–26.9) | 23.1 (20.4–25.3) |
Any comorbidity | ||||
Hypertension, n (%) | 0 | 657 (52) | 82 (54) | 188 (58) |
Diabetes, n (%) | 0 | 330 (26) | 61 (40) | 117 (36) |
Cardiovascular disease, n (%) | 0 | 376 (30) | 56 (37) | 118 (37) |
Tumor, n (%) | 0 | 372 (29) | 32 (21) | 69 (21) |
Chronic liver disease, n (%) | 0 | 165 (13) | 20 (13) | 36 (11) |
Chronic obstructive, n (%) | 0 | 22 (2) | 11 (7) | 19 (6) |
Onset symptoms | ||||
Fever, n (%) | 0 | 474 (38) | 126 (82) | 283 (88) |
Cough, n (%) | 0 | 451 (36) | 124 (81) | 136 (42) |
Headache, n (%) | 0 | 9 (1) | 1 (1) | 5 (2) |
Diarrhoea, n (%) | 0 | 22 (2) | 3 (2) | 2 (1) |
